Shigeki Shibata

Shigeki Shibata has been instrumental in the clinical development and mechanistic characterization of ixazomib, the first oral proteasome inhibitor approved for multiple myeloma, which transformed maintenance therapy by enabling convenient oral triplet regimens. His research has compared the binding kinetics and subunit selectivity of ixazomib versus bortezomib and carfilzomib, revealing distinct pharmacological profiles that underlie their different efficacy and toxicity patterns. He has investigated immunoproteasome-selective inhibitors as potential cancer immunotherapy agents. His work on proteasome biology has identified biomarkers for predicting proteasome inhibitor sensitivity in individual patients.